(Q44529440)

English

Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa

scientific article published in August 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

4

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

author name string

Marin D

1

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Marktel S

2

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Bua M

3

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Franceschino A

5

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Nathan I

6

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Foot N

7

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Crawley C

8

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Na Nakorn T

9

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Olavarria E

10

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Lennard A

11

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Neylon A

12

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

O'Brien SG

13

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Goldman JM

14

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Apperley JF

15

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

publication date

1 August 2003

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

17

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

1448-1453

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

https://scigraph.springernature.com/pub.10.1038/sj.leu.2402996

0 references

Factors affecting duration of survival after onset of blastic transformation of chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402996

21 January 2018

Chronic myeloid leukemia: current treatment options

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402996

21 January 2018

Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402996

21 January 2018

Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402996

21 January 2018

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402996

21 January 2018

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402996

21 January 2018

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402996

21 January 2018

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402996

21 January 2018

Characteristics of accelerated disease in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402996

21 January 2018

A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402996

21 January 2018

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402996

21 January 2018

Normal primitive haemopoietic progenitors are more frequent than their leukaemic counterpart in newly diagnosed patients with chronic myeloid leukaemia but rapidly decline with time

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402996

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.LEU.2402996

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44529440&oldid=2026938704"